Global Atopic Dermatitis Treatment Market: Consolidation to Drive Development of Novel Therapies, observes FMI

Some of the prominent players operating in the atopic dermatitis treatment market are Anacor Pharmaceutical Inc., Regeneron Pharmaceuticals, Novartis International AG, Astellas Pharma Inc., Pfizer, with Astellas and Novartis holding their sway for the past few decades, notes Future Market Insights (FMI). Other top players include Fujisawa Healthcare, Inc., Bristol-Myers Squibb, Bayer AG, Galderma SA, Allergan Plc., MedPointe Pharmaceuticals, Encore Dermatology, and Sanofi SA. While Astellas Pharma has still hold significant clout in the atopic dermatitis treatment market, the presence of Novartis has faded in recent years. However, its products and brands still continue to hold traction among doctors who prescribe systemic immune modulators for the management of atopic dermatitis.

Several prominent players are entering into strategic partnerships with companies that have products in advanced stages of production. This enables them to expedite product approvals and bolster the marketing strategies of their products. Some are focused on acquiring clinical-stage biopharmaceutical companies to consolidate their market positions. Several players are increasingly focused on research and development (R&D) activities related to novel biologics, especially with regard to developing interleukin inhibitors. Making innovative product launches has been the prime strategy to garner a sustained share in the atopic dermatitis treatment market for quite some time.

The global market for atopic dermatitis treatment is projected to surge from US$7,225 million in 2017 to touch a valuation of US$23,992.3 million by the end of 2027. The market is anticipated to expand at a CAGR of 12.8% from 2017 to 2027, with the revenue of the market growing by more than four times during the same period.

The study presented here is based on a report by Future Market Insights (FMI) titled, “Atopic Dermatitis Treatment Market: Global Industry Analysis 2012–2016 and Opportunity Assessment 2017–2027.”

The various drug types used in the treatment of atopic dermatitis are corticosteroids, immunosuppressants, calcineurin inhibitors, biologic therapy, antibiotics, and PDE-4 inhibitor, antibiotics, emollients, and antihistamines. Of these, corticosteroids accounted for the leading share, vis-à-vis revenue, in the global market. Regionally, North America is set to be the dominant market throughout the forecast period. The dominance of the market is attributed largely to the faster-to-market of a number of novel class of products and is driven by industry consolidations in the region. The regional market is projected to rise at a CAGR of 16.0% from 2017 to 2027 and touch a valuation of US$10,384 million by 2027 end.

Development of Medications with Better Efficacy and Safety Profiles Boosting Market

The growing incidence of atopic dermatitis in the last three decades in various developing and developed regions, notably in emerging economies of Asia pacific excluding Japan (APEJ), is a significant factor fortifying the demand for treatments. The launch of novel therapies and new drug classes in these regions, combined with substantial funds on R&D, is a key factor driving the market. The market is expected to benefit immensely from revised reimbursement policies in key regions.

The development of monoclonal antibodies by key players and surging research into novel biologics are prominent aspects accentuating the market. In addition, substantial R&D into novel systemic therapies bodes well for the market. The intensifying need for medications with better efficacy and less side effects is catalyzing research and development in the market. The idiopathic nature of the disease, a disease with no well-known etiology, and its growing morbidities among populations living in dry climate countries are key aspects spurring the demand for therapies to meet the unmet needs.

High Pricing for Biologics Used for Treatment Key Constraint 

The high pricing of novel therapies and a significant number of risks of some common drugs used in the treatment of atopic dermatitis are notable factors likely to hinder the growth of the market. The emergence of some notable allergic reactions and severe eye problems associated with some drugs in recent years may hamper their demand among some populations. Nevertheless, the focus of pharmaceutical players on novel systemic therapies is expected to favorably impact the growth of the market.

Furthermore, the wave of consolidation in major regions such as North America and Europe, prominent companies acquiring small regional players, is a prominent trend expected to augur well for the market in the coming years.

Queries regarding these research findings can be addressed to Future Market Insights’ analysts at press@futuremarketinsights.com

About the Author

Sabyasachi Ghosh

Sabyasachi Ghosh is an experienced market research analyst and consultant, with over six years of experience in end-to-end project management. He has worked at numerous leadership positions and has a vast experience of compiling high-quality market research reports. Sabyasachi is an authoritative voice in the market research sector, and has been cited in top industry publications. He is a travel junkie, and loves to travel far and wide with his friends.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may also like these